Global Chronic Obstructive Pulmonary Disorder Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 92

Report ID: 1522

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time.
The growth of the global chronic obstructive pulmonary disease (COPD) market is expected to be fueled by a high number of new, more efficacious and convenient products entering the market and commanding a greater value compared to the therapies already existing in the market. Another major factor propelling the growth of the market is the introduction of novel innovations like ultrasonic nebulizers, which are superior to the existing jet nebulizers. The competitive environment is expected to intensify with an increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions. The market for COPD drugs shows potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technology, many companies are focusing and collaborating to develop innovative COPD drugs and treatments.
In 2018, the global Chronic Obstructive Pulmonary Disorder market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Chronic Obstructive Pulmonary Disorder status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Chronic Obstructive Pulmonary Disorder development in United States, Europe and China.

The key players covered in this study
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma

Market segment by Type, the product can be split into
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others

Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Chronic Obstructive Pulmonary Disorder status, future forecast, growth opportunity, key market and key players.
To present the Chronic Obstructive Pulmonary Disorder development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Chronic Obstructive Pulmonary Disorder are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Chronic Obstructive Pulmonary Disorder Market Size Growth Rate by Type (2014-2025)
1.4.2 Short-Acting Bronchodilators
1.4.3 Corticosteroids
1.4.4 Methylxanthines
1.4.5 Long-Acting Bronchodilators
1.4.6 Phosphodiesterase-4 Inhibitors
1.4.7 Others
1.5 Market by Application
1.5.1 Global Chronic Obstructive Pulmonary Disorder Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Chronic Obstructive Pulmonary Disorder Market Size
2.2 Chronic Obstructive Pulmonary Disorder Growth Trends by Regions
2.2.1 Chronic Obstructive Pulmonary Disorder Market Size by Regions (2014-2025)
2.2.2 Chronic Obstructive Pulmonary Disorder Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Chronic Obstructive Pulmonary Disorder Market Size by Manufacturers
3.1.1 Global Chronic Obstructive Pulmonary Disorder Revenue by Manufacturers (2014-2019)
3.1.2 Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Chronic Obstructive Pulmonary Disorder Market Concentration Ratio (CR5 and HHI)
3.2 Chronic Obstructive Pulmonary Disorder Key Players Head office and Area Served
3.3 Key Players Chronic Obstructive Pulmonary Disorder Product/Solution/Service
3.4 Date of Enter into Chronic Obstructive Pulmonary Disorder Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Chronic Obstructive Pulmonary Disorder Market Size by Type (2014-2019)
4.2 Global Chronic Obstructive Pulmonary Disorder Market Size by Application (2014-2019)

5 United States
5.1 United States Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
5.2 Chronic Obstructive Pulmonary Disorder Key Players in United States
5.3 United States Chronic Obstructive Pulmonary Disorder Market Size by Type
5.4 United States Chronic Obstructive Pulmonary Disorder Market Size by Application

6 Europe
6.1 Europe Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
6.2 Chronic Obstructive Pulmonary Disorder Key Players in Europe
6.3 Europe Chronic Obstructive Pulmonary Disorder Market Size by Type
6.4 Europe Chronic Obstructive Pulmonary Disorder Market Size by Application

7 China
7.1 China Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
7.2 Chronic Obstructive Pulmonary Disorder Key Players in China
7.3 China Chronic Obstructive Pulmonary Disorder Market Size by Type
7.4 China Chronic Obstructive Pulmonary Disorder Market Size by Application

8 Japan
8.1 Japan Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
8.2 Chronic Obstructive Pulmonary Disorder Key Players in Japan
8.3 Japan Chronic Obstructive Pulmonary Disorder Market Size by Type
8.4 Japan Chronic Obstructive Pulmonary Disorder Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
9.2 Chronic Obstructive Pulmonary Disorder Key Players in Southeast Asia
9.3 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size by Type
9.4 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size by Application

10 India
10.1 India Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
10.2 Chronic Obstructive Pulmonary Disorder Key Players in India
10.3 India Chronic Obstructive Pulmonary Disorder Market Size by Type
10.4 India Chronic Obstructive Pulmonary Disorder Market Size by Application

11 Central & South America
11.1 Central & South America Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
11.2 Chronic Obstructive Pulmonary Disorder Key Players in Central & South America
11.3 Central & South America Chronic Obstructive Pulmonary Disorder Market Size by Type
11.4 Central & South America Chronic Obstructive Pulmonary Disorder Market Size by Application

12 International Players Profiles
12.1 GSK
12.1.1 GSK Company Details
12.1.2 Company Description and Business Overview
12.1.3 Chronic Obstructive Pulmonary Disorder Introduction
12.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.1.5 GSK Recent Development
12.2 Pfizer
12.2.1 Pfizer Company Details
12.2.2 Company Description and Business Overview
12.2.3 Chronic Obstructive Pulmonary Disorder Introduction
12.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.2.5 Pfizer Recent Development
12.3 Merck
12.3.1 Merck Company Details
12.3.2 Company Description and Business Overview
12.3.3 Chronic Obstructive Pulmonary Disorder Introduction
12.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.3.5 Merck Recent Development
12.4 Novartis
12.4.1 Novartis Company Details
12.4.2 Company Description and Business Overview
12.4.3 Chronic Obstructive Pulmonary Disorder Introduction
12.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.4.5 Novartis Recent Development
12.5 AstraZeneca
12.5.1 AstraZeneca Company Details
12.5.2 Company Description and Business Overview
12.5.3 Chronic Obstructive Pulmonary Disorder Introduction
12.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.5.5 AstraZeneca Recent Development
12.6 Boehringer Ingelheim
12.6.1 Boehringer Ingelheim Company Details
12.6.2 Company Description and Business Overview
12.6.3 Chronic Obstructive Pulmonary Disorder Introduction
12.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.6.5 Boehringer Ingelheim Recent Development
12.7 Teva Pharmaceuticals
12.7.1 Teva Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 Chronic Obstructive Pulmonary Disorder Introduction
12.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.7.5 Teva Pharmaceuticals Recent Development
12.8 Ario Pharma
12.8.1 Ario Pharma Company Details
12.8.2 Company Description and Business Overview
12.8.3 Chronic Obstructive Pulmonary Disorder Introduction
12.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.8.5 Ario Pharma Recent Development
12.9 Roche
12.9.1 Roche Company Details
12.9.2 Company Description and Business Overview
12.9.3 Chronic Obstructive Pulmonary Disorder Introduction
12.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.9.5 Roche Recent Development
12.10 Ache
12.10.1 Ache Company Details
12.10.2 Company Description and Business Overview
12.10.3 Chronic Obstructive Pulmonary Disorder Introduction
12.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
12.10.5 Ache Recent Development
12.11 Almirall
12.12 Aquinox Pharmaceuticals
12.13 Asmacure
12.14 Astellas Pharma

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details